Literature DB >> 6508713

Metabolic and physiological differences between zero-flow and low-flow myocardial ischemia: effects of L-acetylcarnitine.

D J Paulson, M J Schmidt, J Romens, A L Shug.   

Abstract

The metabolic and physiologic differences between low-flow and zero-flow ischemia of varying duration were compared in the isolated perfused rat heart. Hearts subjected to 60 and 90 minutes of zero-flow ischemia recovered less cardiac work than hearts subjected to low-flow ischemia. Low-flow ischemia caused a build-up of both myocardial long-chain acyl coenzyme A and acyl carnitine esters, while zero-flow ischemia produced no change in long-chain acyl carnitine and only a transient increase in long-chain acyl coenzyme A. High energy phosphate depletion was greater in zero-flow ischemia. Perfusion with excess free fatty acids decreased the recovery of cardiac work after low-flow ischemia but had no effect after repeated episodes of zero-flow ischemia. L-Acetylcarnitine improved the recovery of cardiac work after low-flow ischemia in hearts perfused with 0.4 and 1.2 mM palmitate. With zero-flow ischemia, L-acetylcarnitine had no effect on the recovery of cardiac work in hearts perfused with 0.4 mM palmitate and a slight but statistically significant effect with 1.2 mM palmitate. Possible protective mechanisms of L-acetylcarnitine against ischemic damage are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508713     DOI: 10.1007/bf01910484

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  30 in total

Review 1.  Myocardial ischemia (first of three parts).

Authors:  L D Hillis; E Braunwald
Journal:  N Engl J Med       Date:  1977-04-28       Impact factor: 91.245

2.  Microdetermination of (-)carnitine and carnitine acetyltransferase activity.

Authors:  R Parvin; S V Pande
Journal:  Anal Biochem       Date:  1977-05-01       Impact factor: 3.365

3.  Effects of regional ischemia on metabolism of glucose and fatty acids. Relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia.

Authors:  L H Opie
Journal:  Circ Res       Date:  1976-05       Impact factor: 17.367

4.  Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction.

Authors:  M F Oliver; V A Kurien; T W Greenwood
Journal:  Lancet       Date:  1968-04-06       Impact factor: 79.321

5.  Effect of pressure development on glucose and palmitate metabolism in perfused heart.

Authors:  M F Crass; E S McCaskill; J C Shipp
Journal:  Am J Physiol       Date:  1969-06

6.  Effects of excess free fatty acids on mechanical and metabolic function in normal and ischemic myocardium in swine.

Authors:  A J Liedtke; S Nellis; J R Neely
Journal:  Circ Res       Date:  1978-10       Impact factor: 17.367

7.  Effects of L-carnitine on tissue levels of acyl carnitine, acyl coenzyme A and high energy phosphate in ischemic dog hearts.

Authors:  Y Suzuki; T Kamikawa; A Kobayashi; Y Masumura; N Yamazaki
Journal:  Jpn Circ J       Date:  1981-06

8.  Changes in tissue levels of carnitine and other metabolites during myocardial ischemia and anoxia.

Authors:  A L Shug; J H Thomsen; J D Folts; N Bittar; M I Klein; J R Koke; P J Huth
Journal:  Arch Biochem Biophys       Date:  1978-04-15       Impact factor: 4.013

9.  Improved pacing tolerance of the ischemic human myocardium after administration of carnitine.

Authors:  J H Thomsen; A L Shug; V U Yap; A K Patel; T J Karras; S L DeFelice
Journal:  Am J Cardiol       Date:  1979-02       Impact factor: 2.778

10.  The efflux of L-carnitine from cells in culture (CCL 27).

Authors:  P Mølstad
Journal:  Biochim Biophys Acta       Date:  1980-03-27
View more
  15 in total

Review 1.  Myocardial fatty acid oxidation during ischemia and reperfusion.

Authors:  R Lerch; C Tamm; I Papageorgiou; R H Benzi
Journal:  Mol Cell Biochem       Date:  1992-10-21       Impact factor: 3.396

2.  Protective effects of propionyl-L-carnitine during ischemia and reperfusion.

Authors:  A Shug; D Paulson; R Subramanian; V Regitz
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

3.  Delineation of the influence of propionylcarnitine on the accumulation of long-chain acylcarnitines and electrophysiologic derangements evoked by hypoxia in canine myocardium.

Authors:  K A Yamada; D J Dobmeyer; E M Kanter; S G Priori; P B Corr
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

4.  Short-term hemodynamic effects of intravenous propionyl-L-carnitine in anesthetized dogs.

Authors:  A Cevese; F Schena; G Cerutti
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

5.  Protective effect of propionyl-L-carnitine against ischaemia and reperfusion-damage.

Authors:  R Ferrari; C Ceconi; S Curello; E Pasini; O Visioli
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

Review 6.  Intracellular transport of lipids.

Authors:  J F Glatz; G J van der Vusse
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

Review 7.  Alterations in fatty acid oxidation in ischemic and reperfused myocardium.

Authors:  X Q Huang; A J Liedtke
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

Review 8.  Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders.

Authors:  Carmen Mingorance; Rosalía Rodríguez-Rodríguez; María Luisa Justo; María Alvarez de Sotomayor; María Dolores Herrera
Journal:  Vasc Health Risk Manag       Date:  2011-03-28

Review 9.  Significance of cytoplasmic fatty acid-binding protein for the ischemic heart.

Authors:  J F Glatz; M M Vork; G J van der Vusse
Journal:  Mol Cell Biochem       Date:  1993 Jun 9-23       Impact factor: 3.396

10.  Effects of POCA on metabolism and function in the ischemic rat heart.

Authors:  D J Paulson; J J Noonan; K M Ward; H Stanley; A Sherratt; A L Shug
Journal:  Basic Res Cardiol       Date:  1986 Mar-Apr       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.